These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11466405)

  • 21. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
    Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
    J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
    Ghose A; Iakhnina E; Spaner D; Tartaglia J; Berinstein NL
    Hum Gene Ther; 2000 Jun; 11(9):1289-301. PubMed ID: 10890739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
    Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M
    J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
    Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
    J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
    Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N
    J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
    Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
    Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.
    López-Albaitero A; Mailliard R; Hackman T; Andrade Filho PA; Wang X; Gooding W; Ferrone S; Kalinski P; Ferris RL
    J Immunother; 2009 Jun; 32(5):465-73. PubMed ID: 19609238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
    Srinivas O; Larrieu P; Duverger E; Boccaccio C; Bousser MT; Monsigny M; Fonteneau JF; Jotereau F; Roche AC
    Bioconjug Chem; 2007; 18(5):1547-54. PubMed ID: 17602511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.
    Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
    Med Oncol; 2006; 23(2):273-82. PubMed ID: 16720928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
    Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
    J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.
    Barrio MM; Abes R; Colombo M; Pizzurro G; Boix C; Roberti MP; Gélizé E; Rodriguez-Zubieta M; Mordoh J; Teillaud JL
    PLoS One; 2012; 7(7):e40311. PubMed ID: 22768350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.
    Blanchet JS; Valmori D; Dufau I; Ayyoub M; Nguyen C; Guillaume P; Monsarrat B; Cerottini JC; Romero P; Gairin JE
    J Immunol; 2001 Nov; 167(10):5852-61. PubMed ID: 11698460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
    Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
    J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.
    Shaif-Muthana M; McIntyre C; Sisley K; Rennie I; Murray A
    Cancer Res; 2000 Nov; 60(22):6441-7. PubMed ID: 11103811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.